GlassScriptPhysician profile
Roger Barnes
NPI 1902078587
$2,204.06
in general payments reported to CMS, 2019-2025
21 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $431 · 2022: $342 · 2023: $483 · 2024: $610 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.35 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $777.27 | 2021-2025 | |
| Novo Nordisk INC | $292.53 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $234.80 | 2021-2023 | Otezla, Repatha |
| Corcept Therapeutics | $159.69 | 2025 | Korlym |
| Cequr Corporation | $146.05 | 2024-2025 | Cequr Simplicity |
| Medtronic, INC. | $109.12 | 2022 | |
| Astellas Pharma US INC | $90.44 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $79.37 | 2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $67.75 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.61 | 2021-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $40.94 | 2021-2022 | |
| Allergan, INC. | $23.75 | 2021 | |
| Dexcom, INC. | $20.51 | 2024 | Dexcom G6 Transmitter |
| Clarus Therapeutics INC. | $18.53 | 2021 | |
| Lilly USA, LLC | $17.47 | 2023 | Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $17.46 | 2023 | Gemtesa |
| Pfizer INC. | $16.66 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.38 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.50 | 2023 | |
| Mylan Specialty L.P. | $13.39 | 2023 | Yupelri |
| Genentech USA, INC. | $7.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.